Lab Tools Break Out, Now Orders Must Confirm

Life-science tools and diagnostics names are rallying as sector breadth improves, and several have broken to fresh highs. Recent market data show Twist Bioscience ( $TWST Twist Bioscience Corporation $96.65 ) up 59.6% in a month, 10x Genomics ( $TXG 10x Genomics, Inc. $35.73 ) up 50.9% in a month, and Biodesix ( $BDSX Biodesix, Inc. $20.04 ) up 34.2% in a month. With moves like these, the next phase will depend on orders, consumables pull-through, and how much room for scale-driven margin improvement is left in the model.

This basket spans different business models across research tools and diagnostics, but the why-now is the same. Momentum has shifted in their favor, and the market is looking for confirmation that lab budgets can support continued growth and that gross margins can expand without aggressive price cuts. That is the test for extending these breakouts.

Twist Bioscience: Raising Guidance With Margin Goals

Twist Bioscience reported record second-quarter revenue of $110.7 million, up about 19% year over year, and raised its fiscal 2026 outlook to $442 million to $447 million. Management reiterated a goal of adjusted EBITDA breakeven in the fiscal fourth quarter and expects third-quarter revenue of $114 million to $115 million, with next-generation sequencing (NGS) as the growth driver, according to the company’s May update.

The mix still tilts toward recurring consumables. DNA Synthesis and Protein Solutions grew strongly, and NGS grew both year over year and sequentially. Gross margin improved to 51.6% in the quarter, and the company continues to target full-year gross margin above 52%. After 13 consecutive quarters of sequential growth, the market will be watching whether NGS demand and pricing can sustain margin improvement without heavier discounts.

10x Genomics: Consumables Lead As Instruments Lag

10x Genomics posted first-quarter revenue of $150.8 million, down 3% year over year, but up 9% excluding a one-time license and royalty item in the prior year. Management called out double-digit growth in Single Cell consumables reaction volumes and double-digit growth in Spatial consumables revenue, while instrument revenue trailed last year’s pace. Gross margin improved to 70%, and the company maintained its full-year 2026 revenue outlook of $600 million to $625 million.

The market is weighing whether healthy consumables pull-through can offset a slower instrument cycle. If placements stabilize as budget visibility improves, expense ratios could improve into the back half. Competitive intensity in single-cell and spatial analysis remains a risk if pricing pressure returns.

Biodesix: Volumes And Pricing Power Drive Gains

Biodesix delivered 42% year-over-year revenue growth in the first quarter to $25.6 million, driven by a 29% increase in test volumes to 17,800 and higher average revenue per test as payer coverage expanded. Gross margin was 84% in the quarter, or 82% excluding a one-time tax recovery. Management raised full-year 2026 revenue guidance to $108 million to $114 million and reiterated progress toward adjusted EBITDA profitability as sales productivity and its Development Services pipeline scale.

For a micro-cap that has rallied quickly, the near-term debate is execution. Investors will be watching volumes, reimbursement durability, and the pace of operating-expense efficiency. Any wobble in payer mix or test adoption could hit gross margin and force a slower trajectory.

Budgets And Pricing Are The Test

These are tools and diagnostics businesses, and they still run on customer budgets. Any tightening at biopharma, academic, or hospital labs could hit orders and instrument placements, with ripple effects on consumables pull-through. Pricing is a second swing factor. If discounting returns to win share, gross-margin expansion could stall. That same trade-off between growth and margin is front and center in InMode’s Breakout Puts July Margins in Focus.

Momentum also cuts both ways. High-velocity runs often retrace on a soft datapoint. This is not unique to healthcare. The dynamic showed up in cyclicals when breadth broadened earlier this year in Trucking rally broadens, but pricing is the test.

How Investors Will Judge The Next Leg

For $TWST Twist Bioscience Corporation $96.65 , watch whether NGS remains the third-quarter growth driver and whether gross margin holds above the full-year target while expenses stay disciplined.

For $TXG 10x Genomics, Inc. $35.73 , look for stabilization in instruments alongside continued consumables growth, and whether the full-year revenue outlook holds as budgets free up.

For $BDSX Biodesix, Inc. $20.04 , test volumes, average revenue per test, and payer coverage are the swing factors, along with continued operating-spend efficiency. If those pieces line up, the market may be willing to extend these breakouts beyond a one-month burst.